

Mijin Yun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3215125/publications.pdf>

Version: 2024-02-01

177
papers

4,887
citations

94433

37
h-index

128289

60
g-index

187
all docs

187
docs citations

187
times ranked

6725
citing authors

#	ARTICLE	IF	CITATIONS
1	Looking Back at 60 years of History to Pave a New Path for the Korean Society of Nuclear Medicine: Interviews with Senior Professors. <i>Nuclear Medicine and Molecular Imaging</i> , 2022, 56, 1-2.	1.0	0
2	Impact of Exogenous Treatment with Histidine on Hepatocellular Carcinoma Cells. <i>Cancers</i> , 2022, 14, 1205.	3.7	4
3	Diagnostic Utility of Somatostatin Receptor 2A Immunohistochemistry for Tumor-induced Osteomalacia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	3.6	0
4	Interrelation of striatal dopamine, brain metabolism and cognition in dementia with Lewy bodies. <i>Brain</i> , 2022, 145, 4448-4458.	7.6	9
5	Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization. <i>Clinical Nuclear Medicine</i> , 2022, 47, e437-e443.	1.3	2
6	Association of β -Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra. <i>Neurology</i> , 2022, 98, .	1.1	10
7	Extracellular Citrate Treatment Induces HIF1 α Degradation and Inhibits the Growth of Low-Glycolytic Hepatocellular Carcinoma under Hypoxia. <i>Cancers</i> , 2022, 14, 3355.	3.7	1
8	Serum glucose excretion after Roux-en-Y gastric bypass: a potential target for diabetes treatment. <i>Gut</i> , 2021, 70, 1847-1856.	12.1	19
9	Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease. <i>Nutrition</i> , 2021, 83, 111090.	2.4	36
10	The pattern of FP-CIT PET in pure white matter hyperintensities-related vascular parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 1-6.	2.2	2
11	Metabolic activity assessment by 18 F-fluorodeoxyglucose positron emission tomography in patients with hepatocellular carcinoma undergoing Yttrium-90 transarterial radioembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1679-1684.	2.8	1
12	Relationship between Hearing Loss and Dementia Differs According to the Underlying Mechanism.		

#	ARTICLE	IF	CITATIONS
19	Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1-11.	2.8	1
20	Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies. <i>Scientific Reports</i> , 2021, 11, 14394.	3.3	7
21	Postganglionic Sudomotor Dysfunction and Brain Glucose Hypometabolism in Patients with Multiple System Atrophy. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1247-1256.	2.8	2
22	The role of graphene patterning in field-effect transistor sensors to detect the tau protein for Alzheimer's disease: Simplifying the immobilization process and improving the performance of graphene-based immunosensors. <i>Biosensors and Bioelectronics</i> , 2021, 192, 113519.	10.1	17
23	PET/CT for Brain Amyloid. <i>Clinical Nuclear Medicine</i> , 2021, 46, e133-e140.	1.3	3
24	Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1041-1051.	4.4	11
25	Metabolic tumour volume on 18F-FDG PET/CT predicts extended pathological T stages in patients with renal cell carcinoma at staging. <i>Scientific Reports</i> , 2021, 11, 23486.	3.3	2
26	Predictors of 18F-sodium fluoride uptake in patients with stable coronary artery disease and adverse plaque features on computed tomography angiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 58-66.	1.2	50
27	Effect of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on gluconeogenesis in proximal renal tubules. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 373-382.	4.4	22
28	Distinguishing between dementia with Lewy bodies and Alzheimer's disease using metabolic patterns. <i>Neurobiology of Aging</i> , 2020, 87, 11-17.	3.1	15
29	Neural Correlates of Cognitive Performance in Alzheimer's Disease- and Lewy Bodies-Related Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 873-885.	2.6	4
30	Modified parylene-N films as chemical microenvironments for differentiation and spheroid formation of osteoblast cells. <i>Scientific Reports</i> , 2020, 10, 15219.	3.3	3
31	Dysautonomia Is Linked to Striatal Dopamine Deficits and Regional Cerebral Perfusion in Early Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2020, 45, e342-e348.	1.3	10
32	Clinical and Striatal Dopamine Transporter Predictors of Mild Behavioral Impairment in Drug-Naive Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2020, 45, e463-e468.	1.3	9
33	Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells. <i>PLoS ONE</i> , 2020, 15, e0240107.	2.5	5
34	Glucose Loading Enhances the Value of 18F-FDG PET/CT for the Characterization and Delineation of Cerebral Gliomas. <i>Cancers</i> , 2020, 12, 1977.	3.7	4
35	Multi-slice representational learning of convolutional neural network for Alzheimer's disease classification using positron emission tomography. <i>BioMedical Engineering OnLine</i> , 2020, 19, 70.	2.7	12
36	Choroid Plexus as the Best Reference Region for Standardized Uptake Value Analysis on C11-Acetate PET/CT for Grading and Predicting Prognosis in Patients with Cerebral Gliomas. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 274-280.	1.0	5

#	ARTICLE	IF	CITATIONS
37	Clinical and striatal dopamine transporter predictors of β -amyloid in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e1344-e1352.	1.1	17
38	Excessive Astrocytic GABA Causes Cortical Hypometabolism and Impedes Functional Recovery after Subcortical Stroke. <i>Cell Reports</i> , 2020, 32, 107861.	6.4	39
39	Evaluation of an optimal cutoff of parathyroid venous sampling gradient for localizing primary hyperparathyroidism. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 570-580.	2.7	4
40	Dopaminergic Depletion, β -Amyloid Burden, and Cognition in Lewy Body Disease. <i>Annals of Neurology</i> , 2020, 87, 739-750.	5.3	27
41	Semantic Segmentation of White Matter in FDG-PET Using Generative Adversarial Network. <i>Journal of Digital Imaging</i> , 2020, 33, 816-825.	2.9	24
42	Slice-selective learning for Alzheimer's disease classification using a generative adversarial network: a feasibility study of external validation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2197-2206.	6.4	16
43	Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. <i>Journal of Nuclear Medicine</i> , 2020, 61, 626-629.	5.0	65
44	Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells. <i>BMC Cancer</i> , 2020, 20, 332.	2.6	19
45	The critical role of glucose deprivation in epithelial-mesenchymal transition in hepatocellular carcinoma under hypoxia. <i>Scientific Reports</i> , 2020, 10, 1538.	3.3	20
46	Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells. <i>Yonsei Medical Journal</i> , 2020, 61, 587.	2.2	9
47	Association of the Non-Motor Burden with Patterns of Striatal Dopamine Loss in de novo Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1541-1549.	2.8	4
48	The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 113-122.	5.3	16
49	Re-evaluation of the diagnostic performance of ^{11}C -methionine PET/CT according to the 2016 WHO classification of cerebral gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1678-1684.	6.4	31
50	The Prognostic Value of ^{18}F -FDG Uptake in the Supraclavicular Lymph Node (N3c) on PET/CT in Patients With Locally Advanced Breast Cancer With Clinical N3c. <i>Clinical Nuclear Medicine</i> , 2019, 44, e6-e12.	1.3	4
51	Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction. <i>Neurology</i> , 2019, 92, e2015-e2026.	1.1	28
52	Prognostic values of mid-radiotherapy ^{18}F -FDG PET/CT in patients with esophageal cancer. <i>Radiation Oncology</i> , 2019, 14, 27.	2.7	20
53	Peri-Coronary Adipose Tissue Density Is Associated With ^{18}F -Sodium Fluoride Coronary Uptake in Stable Patients With High-Risk Plaques. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2000-2010.	5.3	129
54	Three-Hour Delayed Imaging Improves Assessment of Coronary ^{18}F -Sodium Fluoride PET. <i>Journal of Nuclear Medicine</i> , 2019, 60, 530-535.	5.0	44

#	ARTICLE	IF	CITATIONS
55	Preoperative Metabolic Tumor Volume ^{2.5} Associated with Early Systemic Metastasis in Resected Pancreatic Cancer: A Transcriptome-Wide Analysis. <i>Gut and Liver</i> , 2019, 13, 356-365.	2.9	9
56	Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT: a multicenter retrospective cohort study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 720-726.	6.4	57
57	A hierarchical prognostic model for risk stratification in patients with early breast cancer according to ¹⁸ F-fluorodeoxyglucose uptake and clinicopathological parameters. <i>Cancer Medicine</i> , 2018, 7, 1127-1134.	2.8	7
58	Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas. <i>Clinical Nuclear Medicine</i> , 2018, 43, 311-316.	1.3	12
59	The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1012-1020.	6.4	29
60	The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. <i>Gastric Cancer</i> , 2018, 21, 213-224.	5.3	32
61	Automated cGMP-compliant radiosynthesis of [¹⁸ F]â€PSS232 for brain PET imaging of metabotropic glutamate receptor subtype 5. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 30-37.	1.0	2
62	Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. <i>Journal of Hepatology</i> , 2018, 68, 764-772.	3.7	86
63	Evaluation of 18F-FDG PET/CT Parameters for Detection of Lymph Node Metastasis in Cutaneous Melanoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 39-45.	1.0	14
64	Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2018, 59, 1143.	2.2	27
65	Feasibility of Coronary ¹⁸ F-Sodium Fluoride Positron-Emission Tomography Assessment With the Utilization of Previously Acquired Computed Tomography Angiography. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e008325.	2.6	36
66	Amyloid-Î²-related and unrelated cortical thinning in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2018, 72, 32-39.	3.1	25
67	Different biological behaviors in left-sided pancreatic cancer according to Yonsei criteria: Proposal of a modified Yonsei criteria score. <i>Pancreatology</i> , 2018, 18, 990-995.	1.1	2
68	Lymph Node With the Highest FDG Uptake Predicts Distant Metastasis-Free Survival in Patients With Locally Advanced Nasopharyngeal Carcinoma. <i>Clinical Nuclear Medicine</i> , 2018, 43, e220-e225.	1.3	8
69	Regulation of Acetate Utilization by Monocarboxylate Transporter 1 (MCT1) in Hepatocellular Carcinoma (HCC). <i>Oncology Research</i> , 2018, 26, 71-81.	1.5	25
70	Olfactory dysfunction in Alzheimer's diseaseâ€ and Lewy bodyâ€related cognitive impairment. <i>Alzheimer's and Dementia</i> , 2018, 14, 1243-1252.	0.8	42
71	Azeotropic drying-free aliphatic radiofluorination to produce PET radiotracers in a mixed organic solvent system. <i>Tetrahedron Letters</i> , 2018, 59, 2848-2852.	1.4	4
72	Metabolic characteristics of solid pseudopapillary neoplasms of the pancreas: their relationships with high intensity 18F-FDG PET images. <i>Oncotarget</i> , 2018, 9, 12009-12019.	1.8	10

#	ARTICLE	IF	CITATIONS
73	Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin. <i>Neuro-Oncology</i> , 2017, 19, now174.	1.2	43
74	18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e497-e499.	1.9	47
75	Usefulness of SPECT/CT in Parathyroid Lesion Detection in Patients with Thyroid Parenchymal 99mTc-Sestamibi Retention. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 32-39.	1.0	17
76	Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer. <i>Abdominal Radiology</i> , 2017, 42, 1621-1626.	2.1	19
77	Evaluation of Spleen Glucose Metabolism Using ¹⁸ F-FDG PET/CT in Patients with Febrile Autoimmune Disease. <i>Journal of Nuclear Medicine</i> , 2017, 58, 507-513.	5.0	33
78	18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 251-260.	3.3	25
79	Intestinal Glycolysis Visualized by FDG PET/CT Correlates With Glucose Decrement After Gastrectomy. <i>Diabetes</i> , 2017, 66, 385-391.	0.6	14
80	Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, e35-e40.	1.3	13
81	The clinical utility of splenic fluorodeoxyglucose uptake for diagnosis and prognosis in patients with macrophage activation syndrome. <i>Medicine (United States)</i> , 2017, 96, e7901.	1.0	6
82	[P4496]: EFFECT OF LEWY BODY DISEASE AND ALZHEIMER'S DISEASE ON COGNITION AND BRAIN ATROPHY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1526.	0.8	0
83	Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1984-1994.	6.4	12
84	Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, 34-39.	1.3	15
85	Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-fetoprotein and ¹⁸ F-fluoro-2-deoxyglucose positron emission tomography. <i>Liver International</i> , 2017, 37, 592-599.	3.9	5
86	¹⁸ F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma Patients: A Multicenter Retrospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 730-736.	5.0	42
87	[P4497]: CLINICAL FEATURES AND CORTICAL ATROPHY PATTERNS OF DEMENTIA WITH LEWY BODIES WITH AND WITHOUT AMYLOID β DEPOSITION. <i>Alzheimer's and Dementia</i> , 2017, 13, P1527.	0.8	0
88	Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer. <i>PLoS ONE</i> , 2017, 12, e0172606.	2.5	6
89	Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer. <i>PLoS ONE</i> , 2017, 12, e0175048.	2.5	11
90	Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). <i>Oncotarget</i> , 2016, 7, 65643-65659.	1.8	35

#	ARTICLE	IF	CITATIONS
91	Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer. <i>Medicine (United States)</i> , 2016, 95, e3452.	1.0	16
92	Prognostic Value of Volumetric Parameters on Staging and Posttreatment FDG PET/CT in Patients With Stage IV Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, 347-353.	1.3	23
93	The diagnostic ability of 18F-FDG PET/CT for mediastinal lymph node staging using 18F-FDG uptake and volumetric CT histogram analysis in non-small cell lung cancer. <i>European Radiology</i> , 2016, 26, 4515-4523.	4.5	24
94	Synergic chemoprevention with dietary carbohydrate restriction and supplementation of AMPK-activating phytochemicals. <i>European Journal of Cancer Prevention</i> , 2016, 25, 54-64.	1.3	11
95	A Comparison Study of Esophageal Findings on 18F-FDG PET/CT and Esophagogastroduodenoscopy. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 123-129.	1.0	3
96	Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer. <i>Medicine (United States)</i> , 2016, 95, e2595.	1.0	15
97	Hybridization-based aptamer labeling using complementary oligonucleotide platform for PET and optical imaging. <i>Biomaterials</i> , 2016, 100, 143-151.	11.4	23
98	Prognostic value of FDG-PET volumetric parameters in patients with p16-positive oropharyngeal squamous cell carcinoma who received curative resection followed by postoperative radiotherapy or chemoradiotherapy. <i>Head and Neck</i> , 2016, 38, 1515-1524.	2.0	11
99	Increased 18F-FDG Uptake on PET/CT is Associated With Poor Arterial and Portal Perfusion on Multiphase CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, 296-301.	1.3	2
100	Prognostic Significance of ¹⁸ F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 509-516.	5.0	42
101	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. <i>Annals of Nuclear Medicine</i> , 2016, 30, 279-286.	2.2	16
102	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1638-1645.	6.4	35
103	Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer. <i>Annals of Nuclear Medicine</i> , 2016, 30, 104-113.	2.2	53
104	Metabolomics of Breast Cancer Using High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopy: Correlations with 18F-FDG Positron Emission Tomography-Computed Tomography, Dynamic Contrast-Enhanced and Diffusion-Weighted Imaging MRI. <i>PLoS ONE</i> , 2016, 11, e0159949.	2.5	21
105	¹⁸ F-FDG/PET May Help to Identify a Subgroup of Patients with T1-T2 Breast Cancer and 1-3 Positive Lymph Nodes Who Are at a High Risk of Recurrence after Mastectomy. <i>Cancer Research and Treatment</i> , 2016, 48, 508-517.	3.0	12
106	The Clinical Usefulness of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma. <i>Cancer Research and Treatment</i> , 2016, 48, 928-941.	3.0	10
107	Prognostic value of pretreatment FDG PET in pediatric neuroblastoma. <i>European Journal of Radiology</i> , 2015, 84, 2633-2639.	2.6	26
108	UCP2-induced fatty acid synthase promotes NLRP3 inflammasome activation during sepsis. <i>Journal of Clinical Investigation</i> , 2015, 125, 665-680.	8.2	223

#	ARTICLE	IF	CITATIONS
109	Visceral adiposity is associated with altered myocardial glucose uptake measured by 18FDG-PET in 346 subjects with normal glucose tolerance, prediabetes, and type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2015, 14, 148.	6.8	30
110	The bifunctional autophagic flux by 2-deoxyglucose to control survival or growth of prostate cancer cells. <i>BMC Cancer</i> , 2015, 15, 623.	2.6	18
111	Relationship Between 18F-FDG Uptake on PET and Recurrence Patterns After Curative Surgical Resection in Patients with Advanced Gastric Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1494-1500.	5.0	13
112	Pituitary 18F-FDG Uptake Correlates With Serum TSH Levels in Subjects With Diffuse Thyroid 18F-FDG Uptake. <i>Clinical Nuclear Medicine</i> , 2015, 40, 632-636.	1.3	7
113	Concurrent Bisphosphonate-Related Bilateral Atypical Subtrochanteric Fractures and Osteonecrosis of the Jaw on Bone Scintigraphy. <i>Clinical Nuclear Medicine</i> , 2015, 40, 450-452.	1.3	6
114	The regulation of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase by autophagy in low-glycolytic hepatocellular carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 440-446.	2.1	32
115	The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. <i>Annals of Nuclear Medicine</i> , 2015, 29, 400-408.	2.2	25
116	The Performance of Contrast-Enhanced FDG PET/CT for the Differential Diagnosis of Unexpected Ovarian Mass Lesions in Patients With Nongynecologic Cancer. <i>Clinical Nuclear Medicine</i> , 2015, 40, 97-102.	1.3	12
117	Chronic HMGR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction. <i>Autophagy</i> , 2015, 11, 2089-2101.	9.1	47
118	Risk Stratification of Thyroid Incidentalomas Found on PET/CT: The Value of Iodine Content on Noncontrast Computed Tomography. <i>Thyroid</i> , 2015, 25, 1249-1254.	4.5	7
119	Correlation Analysis and Prognostic Impact of 18F-FDG PET and Excision Repair Cross-Complementation Group 1 (ERCC-1) Expression in Non-Small Cell Lung Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 108-114.	1.0	12
120	Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT. <i>Journal of Gastric Cancer</i> , 2014, 14, 1.	2.5	64
121	The Additional Value of Attenuation Correction CT Acquired During 18F-FDG PET/CT in Differentiating Mature From Immature Teratomas. <i>Clinical Nuclear Medicine</i> , 2014, 39, e193-e196.	1.3	7
122	18F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy. <i>Annals of Nuclear Medicine</i> , 2014, 28, 304-313.	2.2	23
123	Drug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer. <i>Biomaterials</i> , 2014, 35, 2272-2282.	11.4	84
124	<sc>FDG</sc>â€<sc>PET</sc> predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 1118-1125.	3.9	11
125	Clinical Usefulness of 18F-Fluorodeoxyglucose-Positron Emission Tomography in Patients With Locally Advanced Pancreatic Cancer Planned to Undergo Concurrent Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 126-133.	0.8	41
126	The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1898-1906.	6.4	63

#	ARTICLE	IF	CITATIONS
127	The Role of ¹⁸ F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 130-136.	1.0	34
128	Factors Indicating Renal Injury in Pediatric Bilateral Ureteropelvic-junction Obstruction. <i>Urology</i> , 2013, 81, 873-879.	1.0	10
129	Prognostic Value of Metabolic Activity Measured by ¹⁸ F-FDG PET/CT in Patients with Advanced Endometrial Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 257-262.	1.0	10
130	¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography for the evaluation of bone metastasis in patients with gastric cancer. <i>Digestive and Liver Disease</i> , 2013, 45, 769-775.	0.9	16
131	Evaluation of ¹⁸ F-FDG Excretion Patterns in Malignant Obstructive Uropathy. <i>Clinical Nuclear Medicine</i> , 2013, 38, 695-702.	1.3	5
132	Prognostic Value of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Resectable Pancreatic Cancer. <i>Yonsei Medical Journal</i> , 2013, 54, 1377.	2.2	28
133	Risk Stratification of Gallbladder Polyps (≥2 cm) for Surgical Intervention with ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2012, 53, 353-358.	5.0	48
134	Usefulness of Positron Emission Tomography With Fluorine-18-Fluorodeoxyglucose in Predicting Treatment Response in Unresectable Hepatocellular Carcinoma Patients Treated With External Beam Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1172-1178.	0.8	27
135	Correlation Between ¹⁸ F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 169-175.	1.0	21
136	Detection of Cardiovascular System Involvement in Behçet's Disease Using Fluorodeoxyglucose Positron Emission Tomography. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 461-466.	3.4	24
137	Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction. <i>European Radiology</i> , 2011, 21, 1077-1087.	4.5	23
138	Using ¹⁸ F-FDG PET/CT to Detect an Occult Mesenchymal Tumor Causing Oncogenic Osteomalacia. <i>Nuclear Medicine and Molecular Imaging</i> , 2011, 45, 233-237.	1.0	10
139	Evaluation of Bone Metastasis from Hepatocellular Carcinoma Using ¹⁸ F-FDG PET/CT and ^{99m} Tc-HDP Bone Scintigraphy: Characteristics of Soft Tissue Formation. <i>Nuclear Medicine and Molecular Imaging</i> , 2011, 45, 203-211.	1.0	13
140	¹⁸ F-Fluorodeoxyglucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2011, 103, 17-24.	1.7	31
141	Clinical implication of FDG-PET in advanced gastric cancer with signet ring cell histology. <i>Journal of Surgical Oncology</i> , 2011, 104, 566-570.	1.7	25
142	Role of ¹⁸ F-FDG PET Scans in Patients with Helicobacter pylori-Infected Gastric Low-Grade MALT Lymphoma. <i>Gut and Liver</i> , 2011, 5, 308-314.	2.9	17
143	The Utility of F-18 FDG PET/CT in the Evaluation of Pancreatic Intraductal Papillary Mucinous Neoplasm. <i>Clinical Nuclear Medicine</i> , 2010, 35, 776-779.	1.3	66
144	Unusual Gallbladder Metastasis From Non-Small-Cell Lung Cancer Detected by F-18 FDG PET/CT With Intravenous Contrast Enhancement. <i>Clinical Nuclear Medicine</i> , 2010, 35, 635-636.	1.3	9

#	ARTICLE	IF	CITATIONS
145	Physiologic ¹⁸ F-FDG Uptake in the Fallopian Tubes at Mid Cycle on PET/CT. Journal of Nuclear Medicine, 2010, 51, 682-685.	5.0	22
146	Visually Discernible [¹⁸ F]Fluorodeoxyglucose Uptake in Papillary Thyroid Microcarcinoma: A Potential New Risk Factor. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3182-3188.	3.6	43
147	Evaluation of the Role of Hexokinase Type II in Cellular Proliferation and Apoptosis Using Human Hepatocellular Carcinoma Cell Lines. Journal of Nuclear Medicine, 2009, 50, 1525-1532.	5.0	53
148	High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 2426-2432.	7.0	85
149	Measurement of Donor Kidney Functional Renal Volume and Glomerular Filtration Rate to Predict Allograft Function during the Post-Transplantation Period. Nephron Clinical Practice, 2009, 113, c262-c269.	2.3	12
150	The Importance of Acetyl Coenzyme A Synthetase for ¹¹ C-Acetate Uptake and Cell Survival in Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2009, 50, 1222-1228.	5.0	92
151	F-18 FDG PET Scan Findings in Patients With Loeffler's Syndrome. Clinical Nuclear Medicine, 2009, 34, 570-575.	1.3	1
152	Enzymatic properties of the N- and C-terminal halves of human hexokinase II. BMB Reports, 2009, 42, 350-355.	2.4	28
153	Radiation Safety Issues Related to Sentinel Lymph Node Biopsy using Radioactive Colloid: Commentary on "Exposure of Surgical Staff to Radiation". Journal of Breast Cancer, 2009, 12, 121.	1.9	0
154	Usefulness of ¹⁸ F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 759-765.	2.8	61
155	Primary Cancer of the Liver and Biliary Duct. PET Clinics, 2008, 3, 169-186.	3.0	2
156	Thyroid Incidentalomas Identified by ¹⁸ F-FDG PET: Sonographic Correlation. American Journal of Roentgenology, 2008, 191, 598-603.	2.2	50
157	Imaging of Viral Thymidine Kinase Gene Expression by Replicating Oncolytic Adenovirus and Prediction of Therapeutic Efficacy. Yonsei Medical Journal, 2008, 49, 811.	2.2	5
158	Non-functional Pituitary Adenoma Detected on ¹⁸ F-fluorodeoxyglucose Positron Emission Tomography (¹⁸ F-FDG-PET) in a Patient with Mucosa-associated Lymphoid Tissue Lymphoma. Journal of Korean Endocrine Society, 2008, 23, 137.	0.1	1
159	Role of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography in Detecting Extrahepatic Metastasis in Pretreatment Staging of Hepatocellular Carcinoma. Oncology, 2007, 72, 104-110.	1.9	101
160	Assessment of regional GABAA receptor binding using ¹⁸ F-fluoroflumazenil positron emission tomography in spastic type cerebral palsy. NeuroImage, 2007, 34, 19-25.	4.2	25
161	Cortical surface-based analysis of ¹⁸ F-FDG PET: Measured metabolic abnormalities in schizophrenia are affected by cortical structural abnormalities. NeuroImage, 2006, 31, 1434-1444.	4.2	56
162	Relationship between bilateral temporal hypometabolism and EEG findings for mesial temporal lobe epilepsy: Analysis of ¹⁸ F-FDG PET using SPM. Seizure: the Journal of the British Epilepsy Association, 2006, 15, 56-63.	2.0	46

#	ARTICLE	IF	CITATIONS
163	Suture Granuloma Mimicking Recurrent Thyroid Carcinoma on Ultrasonography. <i>Yonsei Medical Journal</i> , 2006, 47, 748.	2.2	40
164	The Clinical Usefulness of 18-Fluorodeoxyglucose Positron Emission Tomography in the Differential Diagnosis, Staging, and Response Evaluation After Concurrent Chemoradiotherapy for Pancreatic Cancer. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 923-929.	2.2	158
165	Fluorodeoxyglucose Positron Emission Tomography in Cutaneous Squamous Cell Carcinoma: Retrospective Analysis of 12 Patients. <i>Dermatologic Surgery</i> , 2006, 31, 442-447.	0.8	1
166	Bilateral breasts involvement in Burkitt's lymphoma detected only by FDG-PET. <i>Clinical Imaging</i> , 2006, 30, 57-59.	1.5	21
167	Variable patterns of positron emission tomography in the assessment of patients with extramammary Paget's disease. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 353-355.	1.2	27
168	The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2005, 46, 953-7.	5.0	33
169	Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1582-8.	5.0	117
170	Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1753-9.	5.0	73
171	Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1621-1630.	6.4	79
172	The Proper Use of PET/CT in Tumoring Imaging. <i>Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association</i> , 2004, 47, 863.	0.1	0
173	Usefulness of 18 F-FDG PET in intrahepatic cholangiocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1467-1472.	6.4	168
174	ROC analysis of ordered subset expectation maximization and filtered back projection technique for FDG-PET in lung cancer. <i>IEEE Transactions on Nuclear Science</i> , 2003, 50, 37-41.	2.0	7
175	18F FDG uptake in the large arteries: A correlation study with the atherogenic risk factors. <i>Seminars in Nuclear Medicine</i> , 2002, 32, 70-76.	4.6	176
176	F-18 FDG Uptake in the Large Arteries. <i>Clinical Nuclear Medicine</i> , 2001, 26, 314-319.	1.3	229
177	Refinement of the Positive Predictive Value of Gallbladder Nonvisualization After Morphine Administration for Acute Cholecystitis Based on the Temporal Pattern of Common Bile Duct Activity. <i>Clinical Nuclear Medicine</i> , 2000, 25, 603-607.	1.3	9